Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab with Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer
NCT06295926Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2024
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in small cell lung cancer (SCLC), sponsored by Peking Union Medical College Hospital. Started Apr 2024; status: recruiting.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06295926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06295926.